US OptionsDetailed Quotes

CDXC240920P2500

Watchlist
  • 0.05
  • 0.000.00%
15min DelayClose Sep 13 16:00 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

Comments

    $ChromaDex (CDXC.US)$
    ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
    ChromaDex Corp. (NASDAQ:CDXC) has announced the expansion of its pharmaceutical-grade Niagen® (nicotinamide riboside chloride) IV and injection offerings to 14 additional leading wellness clinics across the United States. This follows the successful debut of quantities in select clinics last month. Wells Pharma of Houston, a U.S. FDA-registered ...
    $ChromaDex (CDXC.US)$
    ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
    ChromaDex Corp. (NASDAQ:CDXC) has secured U.S. Patent number 10,000,520 C1 for the composition of matter of salt forms of NMNH (dihydronicotinamide mononucleotide), a precursor to NAD+. This patent, co-owned with Queen's University Belfast, grants ChromaDex exclusive rights to the disodium salt form of NMNH. The company now has over ...
    $ChromaDex (CDXC.US)$
    ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
    ChromaDex Corp. (NASDAQ:CDXC) announces the debut of pharmaceutical-grade Niagen® (nicotinamide riboside chloride) for intravenous and injectable use at leading wellness clinics in August. Wells Pharma of Houston, a U.S. FDA-registered 503B outsourcing facility, will compound and distribute Niagen+ to select IV clinics.
    Niagen IV offers superior t...
    $ChromaDex (CDXC.US)$
    NEWS
    ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
Read more